Rezolute (RZLT) Non-Current Debt (2018 - 2022)

Rezolute (RZLT) posted Non-Current Debt of $14.3 million for Q1 2022, up 0.76% sequentially from $14.2 million in Q4 2021.

Analysis

Rezolute (RZLT) Non-Current Debt (2018 - 2022) Analysis & Trends

Rezolute has reported Non-Current Debt for 3 years, with the latest figure at $14.3 million in Q1 2022.

Quarterly Non-Current Debt changed N/A year-over-year to $14.3 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $14.3 million (changed N/A YoY) and the FY2021 annual result came in at $14.0 million, changed N/A from the prior year.
Non-Current Debt climbed to $14.3 million in Q1 2022 per RZLT's latest filing, from $14.2 million in the prior quarter.
Over five years, Non-Current Debt peaked at $14.3 million in Q1 2022 and troughed at $767519.0 in Q2 2018.
A 3-year average of $10.6 million and a median of $14.0 million in 2021 frame the typical range for Non-Current Debt.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	591.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	882.16 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	8.96 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	546.77 Mn
10	Rezolute	477.02 Mn	477.02 Mn	-	-

Historic Data

Download Data